Youmna Ghaleb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7725286/publications.pdf

Version: 2024-02-01

10 papers	218 citations	1478505 6 h-index	1474206 9 g-index
10 all docs	10 docs citations	10 times ranked	486 citing authors

#	Article	IF	Citations
1	Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia. Metabolites, 2022, 12, 262.	2.9	1
2	Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren. Metabolites, 2022, 12, 504.	2.9	1
3	Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. Metabolites, 2021, 11, 564.	2.9	5
4	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. Scientific Reports, 2018, 8, 1943.	3.3	25
5	Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?. European Journal of Human Genetics, 2018, 26, 570-578.	2.8	22
6	Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1. Journal of Clinical Lipidology, 2018, 12, 1374-1382.	1.5	6
7	Plasma proteinâ€convertaseâ€subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 943-953.	4.4	17
8	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Current Atherosclerosis Reports, 2017, 19, 49.	4.8	31
9	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1377-1392.	5.0	23
10	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. Current Atherosclerosis Reports, 2014, 16, 439.	4.8	87